sickle cell

News

Novartis' sickle cell drug gets Breakthrough Therapy designa...

The FDA has granted Breakthrough Therapy designation to Novartis' crizanlizumab for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with

News

GBT heads to FDA with sickle cell drug voxelotor

Global Blood Therapeutics (GBT) has persuaded the FDA to accept biomarker data from a phase III trial of sickle cell disease drug voxelotor as part of a filing for accelerated approval.

News

Novartis drug cuts serious complications in sickle cell dise...

Novartis’ developmental sickle cell disease drug crizanlizumab cut occurrences of a serious complication of the disease that can lead to irreversible or fatal organ damage, according to mid

News

Novartis buys sickle cell biotech Selexys

Swiss pharma takes option on US biotech.

Novartis' sickle cell drug gets Breakthrough Therapy designa...

GBT heads to FDA with sickle cell drug voxelotor

Novartis drug cuts serious complications in sickle cell dise...

Novartis buys sickle cell biotech Selexys

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

sickle cell

Editor's Picks